High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.

doi:10.1158/1078-0432.CCR-15-0340

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2015

Mossoba Miriam E, Halverson David C, Kurlander Roger, Schuver Bazetta Blacklock, Carpenter Ashley, Hansen Brenna, Steinberg Seth M, Ali Syed Abbas, Tageja Nishant, Hakim Frances T, Gea-Banacloche Juan, Sportes Claude, Hardy Nancy M, Hickstein Dennis D, Pavletic Steven Z, Khuu Hanh, Sabatini Marianna, Stroncek David, Levine Bruce L, June Carl H, Mariotti Jacopo, Rixe Olivier, Fojo Antonio Tito, Bishop Michael R, Gress Ronald E, Fowler Daniel H

Abstract excerpt

PURPOSE: We hypothesized that lymphoid-selective host conditioning and subsequent adoptive transfer of sirolimus-resistant allogeneic T cells (T-Rapa), when combined with high-dose sirolimus drug therapy in vivo, would safely achieve antitumor effects while avoiding GVHD. EXPERIMENTAL DESIGN: Patients (n = 10) with metastatic renal cell carcinoma (RCC) were accrued because this disease is relatively refractory to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Immunotherapy, Adoptive

Share to Lymphocyte Depletion

Share to Sirolimus

Share to Transplantation Chimera

Share to Transplantation Conditioning

Share to Transplantation, Homologous

Source

Open in PubMed Open full text

Identifiers

PMID: 26071480
DOI: 10.1158/1078-0432.CCR-15-0340
PMCID: PMC4592398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.PMID 26071480Read ↗

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donorsSemantic proximity Read ↗

Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation.Semantic proximity Read ↗

Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapySemantic proximity Read ↗

Pre-conditioning Modifies the Tumor Microenvironment to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous ImmunitySemantic proximity Read ↗

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapySemantic proximity Read ↗

The strategies to cure cancer patients by eradicating cancer stem-like cellsSemantic proximity Read ↗

Targeting CD45 by gene-edited CAR-T cells for leukemia eradication and hematopoietic stem cell transplantation preconditioningSemantic proximity Read ↗

Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.